Business Paid
Celon Pharma's CPL'36 shows promise
02:20
Celon Pharma reported positive phase II trial results for CPL'36, a PDE10A inhibitor for treating dyskinesia in Parkinson’s disease. The international, placebo-controlled study involved 105 patients receiving either 20 mg, 40 mg, or a placebo for four weeks.
At week four, CPL'36 showed significant improvement in dyskinesia symptoms on…
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
